The approval was based on data from a phase 3 study which included adults with steroid-resistant active PMR who flared on at least 7.5mg per day of prednisone or equivalent during taper. The Food and ...

Clinicians may have an ambivalent attitude about polymyalgia rheumatica, a disabling disease marked by severe muscle pain and stiffness. On the one hand, it is most rewarding to be able to almost ...

The US Food and Drug Administration (FDA) approved sarilumab (Kevzara) today for the treatment of polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or could ...

Learn about polymyalgia rheumatica, temporal arteritis, their symptoms, causes, and treatment options to manage pain, ...

More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...

Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an ...